PMID- 31182960
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2019
DP  - 2019
TI  - The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in 
      Primary Liver Tumors.
PG  - 4304817
LID - 10.1155/2019/4304817 [doi]
LID - 4304817
AB  - Treatment recommendations for primary liver malignancies, including 
      hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), are complex and 
      require a multidisciplinary approach. Despite surgical options that are 
      potentially curative, options for nonsurgical candidates include systemic 
      therapy, radiotherapy (RT), transarterial chemoembolization (TACE), and 
      radiofrequency ablation (RFA). Stereotactic Body Radiation Therapy (SBRT) is now 
      in routine use for the treatment of lung cancer, and there is growing evidence 
      supporting its use in liver tumors. SBRT has the advantage of delivering ablative 
      radiation doses in a limited number of fractions while minimizing the risk of 
      radiation-induced liver disease (RILD) through highly conformal treatment plans. 
      It should be considered in a multidisciplinary setting for the management of 
      patients with unresectable, locally advanced primary liver malignancies and 
      limited treatment options. Recently, the combination of immunotherapy with SBRT 
      has been proposed to improve antitumor effects through engaging the immune 
      system. This review aims at shedding light on the novel concept of the 
      combination strategy of immune-radiotherapy in liver tumors by exploring the 
      evidence surrounding the use of SBRT and immunotherapy for the treatment of HCC 
      and CCA.
FAU - Kreidieh, Malek
AU  - Kreidieh M
AD  - Division of Hematology and Oncology, Department of Internal Medicine, American 
      University of Beirut, Beirut, Lebanon.
FAU - Zeidan, Youssef H
AU  - Zeidan YH
AD  - Department of Radiation Oncology, American University of Beirut Medical Center, 
      Beirut, Lebanon.
FAU - Shamseddine, Ali
AU  - Shamseddine A
AUID- ORCID: 0000-0003-3725-8403
AD  - Division of Hematology and Oncology, Department of Internal Medicine, American 
      University of Beirut, Beirut, Lebanon.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190428
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC6512065
EDAT- 2019/06/12 06:00
MHDA- 2019/06/12 06:01
PMCR- 2019/04/28
CRDT- 2019/06/12 06:00
PHST- 2018/12/28 00:00 [received]
PHST- 2019/03/18 00:00 [revised]
PHST- 2019/03/25 00:00 [accepted]
PHST- 2019/06/12 06:00 [entrez]
PHST- 2019/06/12 06:00 [pubmed]
PHST- 2019/06/12 06:01 [medline]
PHST- 2019/04/28 00:00 [pmc-release]
AID - 10.1155/2019/4304817 [doi]
PST - epublish
SO  - J Oncol. 2019 Apr 28;2019:4304817. doi: 10.1155/2019/4304817. eCollection 2019.